Tools chosen: kalshi_direct claude_news gdelt_news polymarket_related kalshi_related wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi question about whether Oura Health will officially confirm an IPO before Oct 1, 2026. The key drivers are Oura's own statements about IPO timing, its funding/valuation trajectory (a recent large private round often delays an IPO), and the overall 2025-2026 IPO window for consumer health-tech. I'll anchor on the Kalshi price, cross-check Polymarket, and use news search for management statements and banker/filing rumors.

# Current state Oura confidentially filed for a US IPO with the SEC in May 2026 (Wikipedia/CNBC). As of Aug 24, 2026, Bloomberg reports Oura and backers are seeking to raise up to $3B in a US IPO that "could take place as soon as September" 2026 at a ~$16B valuation — but as of the query date the IPO has NOT yet been officially announced/launched; Kalshi prices only 17% for an official announcement before Oct 1, 2026, having fallen sharply (-36% over 30 days) despite the confidential filing and imminent-launch reporting. # Timeline of key events - 2025-09-28: CEO Tom Hale says IPO is "an option" but noncommittal on timing (TechCrunch, confirmed statement). - 2025-10 (Oct 2025): Oura closes $900M Series E at $11B valuation (Glossy/CNBC, confirmed). - 2025-11-11: Hale states "no news on an IPO" while projecting ~$2B 2026 sales (CNBC, confirmed). - 2026-05-21: Oura confidentially files for US IPO with SEC; HQ relocated to San Francisco (CNBC/Wikipedia, confirmed). - 2026-08-24: Bloomberg reports Oura and backers seeking up to $3B raise, IPO possibly "as soon as September" 2026, valuation >$16B (Bloomberg, reported — sourced to "people familiar," not company-confirmed). - 2026-08-25: Multiple outlets (Fox Sports Radio/iHeart) repeat the $3B/$16B valuation target (reported, same underlying Bloomberg source). - Present (query time, likely late Aug/Sept 2026): No official IPO launch/pricing confirmed yet; Kalshi YES at 17%, down from a 30-day high of 53% but up 8pts in the last 7 days. # Event Will Oura Health Oy officially announce (confirm) an IPO before Oct 1, 2026? # Outcomes to forecast - Yes (IPO officially announced/confirmed before Oct 1, 2026) - No (not confirmed by that date) # Kalshi market anchor Current YES price: **17%**. 7-day change: +8pts (recovering). 30-day change: -36pts (sharp decline from a high of 53%). Price range over data window: 9%–53%. Average daily volume: 275 contracts — this is the primary consensus benchmark to beat. # Sub-question answers 1. **Current Kalshi price/trend** — 17% YES, having fallen from a 30-day high of 53% (-36pts) but rebounding +8pts in the last week; volatile market reflecting shifting sentiment on timing. [kalshi_direct] 2. **Executive statements on IPO timing** — Hale was noncommittal in Sept 2025 ("could go public... when the moment is right, we'll let everyone know") and said "no news on an IPO" in Nov 2025. No public confirmation of hiring bankers found in research, but a confidential S-1 was filed May 2026 (a concrete structural step toward IPO). [TechCrunch, CNBC, Wikipedia] 3. **Most recent funding round** — $900M Series E at $11B valuation, Oct 2025. This preceded rather than replaced the IPO push; fresh capital did not stop the company from pursuing a confidential filing seven months later. [Glossy/CNBC] 4. **IPO window for consumer health-tech/wearables 2025-2026** — General IPO market context cited: 202 IPOs raised $44B in 2025 vs. ~400 deals/$140B in 2021 (weaker overall market), per CNBC. No specific comparable wearables IPO identified in research; Oura would be a marquee name if it proceeds. 5. **Base rate for rumored IPOs confirming within ~11 months** — Not directly answered by research; historically, confidentially-filed S-1s often lead to IPOs within 3-9 months, but timing is frequently pushed by market conditions (see Kalshi's own 30-day price collapse as evidence of perceived slippage risk). Comparable Kalshi IPO markets (Perplexity 52%, Airtable 9%, Bloomberg 6%) show wide variance reflecting company-specific uncertainty. 6. **Cross-market signals** — No Polymarket markets found for Oura or "IPO 2026" (0 matches). Kalshi-related IPO markets (Bloomberg 6%, Airtable 9%, Perplexity 52%) show no direct arbitrage signal for Oura specifically. # Key facts (high-confidence, factual) 1. [CNBC/Wikipedia] Oura confidentially filed for a US IPO in May 2026. 2. [Bloomberg, Aug 24 2026] Reported plan to raise up to $3B, valuation >$16B, possible Sept 2026 launch — sourced to unnamed people familiar, not company-confirmed. 3. [Glossy/CNBC] Series E: $900M at $11B valuation, Oct 2025. 4. [Kalshi] YES price 17%, down sharply from 53% high in past 30 days despite bullish Aug news — signals market skepticism or a de-risking event not captured in text sources. 5. [Wikipedia] HQ moved from Finland to San Francisco ahead of US listing. # Cross-market signals - Kalshi related: Perplexity IPO market at 52%, Airtable at 9%, Bloomberg (company) at 6% — no direct Oura correlation. - Polymarket: No Oura or general "IPO 2026" markets found (0 matches). - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - Bloomberg/Fox Sports Radio: IPO "could take place as soon as September" 2026 — speculative, attributed to unnamed sources, not company statement. - CNBC bottom-line synthesis (claude_news tool): suggests IPO before Oct 1 "appears plausible and increasingly likely," but this conflicts with Kalshi's own pricing (17%) and its recent 30-day decline. # Directional lean per outcome - **Yes**: Confidential S-1 already filed (structural progress); Bloomberg reports imminent Sept 2026 timeline; strong revenue growth (~$2B run-rate) supports IPO readiness; HQ relocated to SF signaling US listing intent. - **No**: Kalshi price itself (17%, down from 53%) suggests market participants see meaningful risk of delay past Oct 1; confidential filings often slip past initial informal timelines; CEO's own past comments (Nov 2025) were noncommittal; weak overall 2025 IPO market (fewer deals, less capital raised) increases execution risk. # Gaps / unknowns - No confirmation of banker hiring or roadshow launch dates. - Unclear what caused the -36% 30-day Kalshi price drop despite seemingly bullish Aug news — possibly earlier optimism unwound, or a report of delay not captured in available research. - No base-rate data specifically on confidential-filing-to-IPO conversion timelines. - No confirmation whether "official announcement" (per market rules) requires public S-1 filing, pricing, or actual listing — ambiguity in resolution mechanics could matter given close proximity to Oct 1 close. # Calibration anchors - Kalshi current YES price: 17% (down from 53% high; primary anchor). - Comparable Kalshi IPO markets: Perplexity 52%, Airtable 9%, Bloomberg 6% — wide dispersion, no strong reference class. - Confidential S-1 (May 2026) to Bloomberg-reported Sept 2026 listing would be a ~4-month gap, consistent with typical confidential-filing-to-IPO windows, but Kalshi's decline suggests the market doubts this holds.

1. Both forecasts converge tightly (0.20/0.21) near the Kalshi anchor without deeply grappling with the critical unresolved question flagged in the brief itself: "No confirmation whether 'official announcement' (per market rules) requires public S-1 filing, pricing, or actual listing" — this resolution ambiguity could swing probability significantly either direction (e.g., if a public S-1 flip counts as "announcement," Yes probability should be notably higher given Bloomberg's Sept timeline), yet neither forecaster addresses this ambiguity's impact on their number. 2. Neither forecast interrogates *why* Kalshi cratered from 53% to 17% over 30 days despite Bloomberg's bullish Aug 24 report landing during that same window — the brief explicitly flags this as an unexplained anomaly ("possibly an earlier optimism unwound, or a report of delay not captured") and both forecasters treat the 17% as reliable without adjusting for the possibility that the market is reacting to negative information not present in the evidence brief. 3. The +8pt rebound in the last 7 days (9%→17% range low to current) is mentioned by both but underweighted as a signal — if the market is actively re-pricing upward following the Aug 24 Bloomberg report, extrapolating that momentum toward Oct 1 (5+ weeks away) could argue for a probability closer to 25-30% rather than just a "slight bump" to 20-21%. 4. Both forecasters ignore the base-rate evidence in the brief that "confidentially-filed S-1s often lead to IPOs within 3-9 months" — since the confidential filing was May 2026, the 3-9 month window centers on Aug-Feb 2026/27, meaning Oct 1 falls squarely within a plausible historical conversion window, which arguably supports weighting above the raw Kalshi price rather than merely anchoring to it. 5. Neither forecast discusses tail scenarios such as a delay explicitly announced (which would resolve No firmly and match market skepticism) versus a quiet pricing/launch in the final week of September that could catch the market by surprise — given IPOs often launch with only 1-2 weeks public notice after confidential-to-public S-1 flip, the "no roadshow confirmed yet" fact is less informative this close to a Sept target than either forecaster implies. 6. Both forecasts land at nearly identical numbers (0.20 vs 0.21) with similar reasoning chains, suggesting insufficient independent variance in analysis — given the genuine uncertainty about resolution criteria and the unexplained Kalshi volatility, a wider spread or more explicit sensitivity analysis (e.g., "if public S-1 filing counts, Yes could be 35%; if only pricing/listing counts, Yes could be 12%") would better reflect the evidence brief's acknowledged ambiguity.

23% (54% confidence)

Yes: 23% No: 77%

The Kalshi anchor of 17% deserves respect, but the critique correctly notes the +8pt weekly rebound following Bloomberg's Aug 24 report of a possible September launch, and that Oct 1 sits squarely within the typical 3-9 month confidential-filing-to-IPO conversion window from the May filing. IPOs frequently flip to a public S-1 with only 1-2 weeks notice, so the absence of a confirmed roadshow is less damning than the market's low price implies. However, the unexplained 53%→17% collapse suggests traders may have information about delay or strict resolution criteria (requiring pricing/listing, not just filing) not captured in the brief, so I stay well below coin-flip territory. I land modestly above both forecasts at 23% Yes, giving partial weight to the critique's momentum and base-rate arguments while respecting the market's persistent skepticism.

Total pipeline time: 202.9s